NTR Nutrien Ltd. IFRS Annual reports only
Agricultural Chemicals · NYSE · SEC CIK 1725964 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $26.89B | $25.97B | $29.06B | $37.88B | $27.71B |
| Cost of revenue | $17.60B | $17.49B | $19.61B | $21.59B | $17.45B |
| Gross profit | $8.35B | $7.53B | $8.47B | $15.42B | $9.41B |
| SG&A expense | $600.00M | $644.00M | $626.00M | $565.00M | $477.00M |
| Operating income | $3.74B | $1.86B | $2.75B | $10.81B | $4.78B |
| Interest expense | $746.00M | $765.00M | $797.00M | $521.00M | $492.00M |
| Pretax income | $3.05B | $1.14B | $1.95B | $10.25B | $4.17B |
| Income tax | $752.00M | $436.00M | $670.00M | $2.56B | $989.00M |
| Net income | $2.27B | $674.00M | $1.26B | $7.66B | $3.15B |
| EBITDA | $6.11B | $4.20B | $4.91B | $12.82B | $6.73B |
| EPS (basic) | 4.66 | 1.36 | 2.53 | 14.22 | 5.53 |
| EPS (diluted) | 4.66 | 1.36 | 2.53 | 14.18 | 5.52 |
| Dividends declared per share | — | 2.16 | 2.12 | 1.92 | — |
| Weighted avg. shares (diluted) | 486.52M | 494.37M | 496.99M | 540.01M | 571.29M |
| Balance sheet | |||||
| Cash & equivalents | $701.00M | $853.00M | $941.00M | $901.00M | $499.00M |
| Receivables | $5.67B | $5.39B | $5.40B | $6.19B | $5.37B |
| Inventory | $6.98B | $6.15B | $6.34B | $7.63B | $6.33B |
| Current assets | $14.75B | $13.79B | $14.17B | $16.34B | $13.85B |
| PP&E, netmay include right-of-use assets (IFRS) | $22.75B | $22.60B | $22.46B | $21.77B | $20.02B |
| Goodwill | $12.14B | $12.04B | $12.11B | $12.37B | $12.22B |
| Intangibles | $1.67B | $1.82B | $2.22B | $2.30B | $2.34B |
| Total assets | $52.30B | $51.84B | $52.75B | $54.59B | $49.95B |
| Current liabilities | $11.04B | $12.04B | $12.12B | $14.28B | $12.44B |
| Short-term debt | $873.00M | $1.53B | $1.81B | $2.14B | $1.56B |
| Long-term debt | $9.35B | $8.88B | $8.91B | $8.04B | $7.52B |
| Total debt | $10.22B | $10.41B | $10.73B | $10.18B | $9.08B |
| Total liabilities | $26.94B | $27.40B | $27.55B | $28.72B | $26.25B |
| Shareholders' equity | $25.32B | $24.41B | $25.16B | $25.82B | $23.65B |
| Net debt | $9.52B | $9.56B | $9.79B | $9.28B | $8.58B |
| Shares outstanding | — | 491.03M | 494.55M | 507.25M | 557.49M |
| Cash flow statement | |||||
| Operating cash flow | $4.01B | $3.54B | $5.07B | $8.11B | $3.89B |
| Capital expenditure | $1.88B | $2.02B | $2.42B | $2.25B | $1.78B |
| Free cash flow | $2.12B | $1.51B | $2.65B | $5.86B | $2.11B |
| Investing cash flow | -$1.37B | -$2.13B | -$2.96B | -$2.90B | -$1.81B |
| Financing cash flow | -$2.82B | -$1.45B | -$2.06B | -$4.73B | -$3.00B |
| Depreciation & amortization | $2.37B | $2.34B | $2.17B | $2.01B | $1.95B |
| Stock-based compensation | $163.00M | $37.00M | -$14.00M | $63.00M | $198.00M |
| Dividends paid | $1.06B | $1.06B | $1.03B | $1.03B | $1.04B |
| Share buybacks | $551.00M | $184.00M | $1.05B | $4.52B | $1.03B |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.